Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

3 1 1

What is this study about?

This study focuses on three skin conditions: Hidradenitis Suppurativa (a painful condition causing lumps under the skin), Prurigo Nodularis (a condition causing intensely itchy bumps on the skin), and Vitiligo (a condition where patches of skin lose their color). The study uses Povorcitinib (also known as INCB054707), which is given as tablets that are taken by mouth.

The purpose of this research is to evaluate the long-term safety of Povorcitinib in people who have previously participated in other studies of this medication. The study will continue for up to 36 months, during which participants will continue taking the medication and have their condition monitored.

This is a follow-up study specifically designed for individuals who have already completed treatment with Povorcitinib in previous research studies and have shown improvement in their condition. Throughout the study, doctors will monitor how well the medication continues to work and check for any side effects that might occur with long-term use.

1 Initial assessment

You will receive povorcitinib in tablet form, which is taken orally

Your eligibility will be confirmed based on your previous participation in a povorcitinib study

The doctor will verify that you received benefit from the previous treatment and had no safety concerns

2 Treatment period

The study will continue from August 2025 to May 2029

Regular monitoring will occur throughout the treatment period

The medication will be taken as prescribed for your specific condition:

3 Monitoring for skin conditions

If you have Hidradenitis Suppurativa (a chronic skin condition with lumps), your inflammatory nodules will be counted at each visit

If you have Vitiligo (loss of skin color), changes in the affected areas will be measured using specific assessment tools (F-VASI and T-VASI)

If you have Prurigo Nodularis (itchy skin condition), your itch levels will be assessed using a rating scale, and the severity will be evaluated at each visit

4 Safety monitoring

Any side effects that occur during treatment will be recorded and monitored

Regular health assessments will be conducted throughout the study period

You must follow all safety guidelines, including pregnancy prevention measures as specified in the study requirements

Who Can Join the Study?

  • You must be able to understand and be willing to sign an Informed Consent Form (ICF) – a document that explains the study details and your rights as a participant
  • You must have completed a previous study with povorcitinib (the study medication) without any safety or health concerns
  • You must have experienced positive results from the treatment in the previous study, as determined by your doctor
  • You must have followed all requirements and instructions during the previous study
  • You must be willing to use appropriate birth control methods and avoid pregnancy or fathering children during the study
  • You must be willing and able to follow all study procedures and requirements
  • You must be an adult or adolescent (12 years or older)
  • Both men and women can participate in the study

Who Cannot Join the Study?

  • Current pregnancy or breastfeeding
  • People under 18 years of age
  • Active or chronic infections, including tuberculosis (a bacterial infection affecting the lungs)
  • History of cancer in the past 5 years (except successfully treated non-melanoma skin cancer)
  • Serious heart conditions or uncontrolled hypertension (high blood pressure)
  • Severe liver disease or abnormal liver function tests
  • Severe kidney disease or significantly reduced kidney function
  • Current treatment with other investigational drugs
  • Known allergic reactions to similar medications
  • Serious mental health conditions that could interfere with the study
  • Active substance abuse or addiction
  • Inability to follow study procedures or attend scheduled visits
  • Major surgery planned during the study period
  • Blood disorders or significant abnormalities in blood tests
  • Immunodeficiency conditions or use of medications that severely suppress the immune system

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Other Sites

Site Name City Country Status
Klinikum Oldenburg AöR Oldenburg In Holstein Germany
Centre Hospitalier Universitaire Rouen Rouen France
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania Catania Italy
Medical Center Hera EOOD Sofia Bulgaria
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) Munich Germany
Centre hospitalier universitaire de Liege Liege Belgium
Klinikum Dortmund gGmbH Dortmund Germany
Universitair Ziekenhuis Gent Gent Belgium
Universitaetsklinikum Aachen AöR Aachen Germany
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
Hospital Edouard Herriot Lyon France
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Del Mar Barcelona Spain
Amphia Hospital Breda The Netherlands
Katholisches Klinikum Bochum gGmbH Bochum Germany
Santa Sp. z o.o. Lodz Poland
AZ Sint-Lucas & Volkskliniek Gent Belgium
Complexo Hospitalario Universitario De Pontevedra Pontevedra Spain
Hospital Universitario Virgen De Las Nieves Granada Spain
Centrum Medyczne Oporow Wroclaw Poland
Umbal – Prof. D-R Stoyan Kirkovich AD Stara Zagora Bulgaria
El Hospital Universitario De Gran Canaria Dr. Negrin Las Palmas De Gran Canaria Spain
Clinical Research Group Sp. z o.o. Warsaw Poland
Clinical Research Center Sp. z o.o. Medic-R sp.k. Poznan Poland
Rosenpark Research GmbH Darmstadt Germany
Klinika Ambroziak Sp. z o.o. Warsaw Poland
Klinikum Darmstadt GmbH Darmstadt Germany
Hms GmbH Merzig Germany
Elbe Kliniken Stade-Buxtehude gGmbH Buxtehude Germany
Carpe Diem Centrum Medycyny Estetycznej Warsaw Poland
UNIMED Medical Center EOOD Plovdiv Bulgaria
Mcbk s.c. Iwona Czajkowska Anna Podrazka Szczepaniak Grodzisk Mazowiecki Poland
Jagiellońskie Centrum Innowacji Sp. z o.o. Cracow Poland
Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie Rzeszow Poland
Etg Neuroscience Sp. z o.o. Warsaw Poland
University Of Debrecen Debrecen Hungary
University Teaching Hospital Markusovszky Szombathely Hungary
Dkc Fokus-5 Lzip OOD Sofia Bulgaria
Clintrial s.r.o. Prague Czechia
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p. Wroclaw Poland
General Hospital Of Thessaloniki Papageorgiou Thessaloniki Greece
Diagnostic-consultative center “Aleksandrovska” EOOD Sofia Bulgaria
Universitaetsklinikum Erlangen AöR Erlangen Germany
Universitaetsklinikum Tuebingen AöR Tuebingen Germany
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Centre Hospitalier Le Mans Le Mans France
Hospital Universitario Fundacion Jimenez Diaz Madrid Spain
Universita’ Politecnica Delle Marche Ancona Italy
Universidade De Santiago De Compostela Santiago De Compostela Spain
Andreas Syngros Hospital Of Venereal And Dermatological Diseases Athens Greece
Synexus Polska Sp. z o.o. Poznan Poland
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire De Nice Nice France
Bravis Ziekenhuis Roosendaal The Netherlands
Hopital Prive D Antony Antony France
Hopitaux Drome Nord Romans-Sur-Isere France
Region Sjaelland Holbæk Denmark
University Hospital Ostrava Ostrava Czechia
ASMC – IPSMC – Skin And Venereal Diseases Sofia Bulgaria
Care Clinic Sp. z o.o. Katowice Poland
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara Chaidari Greece
Azienda Ospedaliero Universitaria Pisana Pisa Italy
EMC Instytut Medyczny S.A. Poznan Poland
LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. Dr. Hab. N. Med. Dorota Krasowska Lublin Poland
Hautaerzte Zentrum Hannover Hanover Germany
Dermedic Jacek Zdybski Ostrowiec Swietokrzyski Poland
DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski s.c Osielsko Poland
“HIGH-MED” Przychodnia Specjalistyczna, Poradnia dermatologiczna Warsaw Poland
Polyclinique Courlancy Reims France
DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gębska Chorzow Poland
Grand Hopital De Charleroi Charleroi Belgium
Diagnostic Consultative Centre Ascendent OOD Sofia Bulgaria
Diagnostics And Consultancy Center Pulmed EOOD Plovdiv Bulgaria
Asclepius Medical Center OOD Dupnitsa Bulgaria
Uvynkwryai Mlacfyv Cedeno Huxmaaryzxjxbhrcn Hamburg Germany
Ufkrjuzlzegj Mabzmat Cafbruh Gbejvlizk Groningen The Netherlands
Tmrrzztduco ugd Suiaiyncjsz Bdglkhel Gymx Bad Bentheim Germany
Lxyop ctafrb S C Awgsmpg Kpoycukt Tqzztu Kohzkfqbays Szczecin Poland
Mscwulakk Igraezcokw Chmopntv Shhyvicw Sqa z ofau Warsaw Poland
Hwjfidepxoyzrv Df Mny Mnetdfrl Hwknyzxr Witten Germany
Ndmmkwfmwimb Zxjufh Onihoj Zezsltikvd Mbnlaevjh Lublin Poland
Nmyx Snzysswd Oouxgby Ddcbcpbcurooodw Drletk Bialystok Poland
Fpqbakwy neenrkbfp Mfbpx a Hxfnlck Prague Czechia
Cvppcr Hvvthfpuqju Udanszktvupko Dl Ditvz Dijon France
Acqymrstu Uqb Amsterdam The Netherlands
Ajijeytwbh Pxmgramb Howmiekq Dm Pkfqh Paris France
Aszabwvdvd Pworpukl Hylnewbr Dp Mihgsiatn Marseille France
Ugmqwkexlhsfnrgwahjxi Duxdxllwjpr Atb Duesseldorf Germany
Eytxuoa Ufsxyvpvbrhb Mdskwsc Cwvylum Ryhwqslkk (vclncdo Mbt Rotterdam The Netherlands
Pojntuzcc Ibyheehy Mmmmfmdp Mphzavcdjzun Stzea Wfhreshbbpqf I Acecoxeekuvqr Warsaw Poland
Gbqeti Ulreojbjvy Fzumlctin Frankfurt Germany
Pydkppd Swy z otor Katowice Poland
Dqkbujiirf Snp z omkj Wroclaw Poland
Fadfzlmoj Pudb Le Ipkaafmcbcugq Bsjnnmzal Ddv Hbcpkvil Ujgboeafosxua Li Paz Madrid Spain
Hdyhjdxj Uxigeufdhfvsh Hpdkvqdk Tntvk y Phosps Iaaaxkuf Cgtuhm dvwavivgfzomoifnf (gemx Badalona Spain
Mbdvflu Cpbjrw Mthxhbkwmm Pzsdxz Owg Pleven Bulgaria
Ivckfsns dc Crlvyrnmixge Hkjxklsqixp Uuusvmigeyoiq ds Snqoa Eucwdji (kagstai Saint Priest En Jarez France
Ddexxtedpljv Qrdhm Mainz Germany
Hgrttyv Huvpr Mupkwk &kquoom 1 rku Ghdwkbt Eqhenb Creteil France
Zaalbfn Mhl Sax z ofzx Lublin Poland
Cyygabkeo Ucorvlbsjmfzvj Sdkwhuege Woluwe-Saint-Lambert Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Recruiting
29.08.2025
Belgium Belgium
Recruiting
29.08.2025
Bulgaria Bulgaria
Recruiting
29.08.2025
Czechia Czechia
Not yet recruiting
29.08.2025
Denmark Denmark
Not yet recruiting
29.08.2025
France France
Recruiting
29.08.2025
Germany Germany
Recruiting
29.08.2025
Greece Greece
Recruiting
29.08.2025
Hungary Hungary
Not yet recruiting
29.08.2025
Italy Italy
Recruiting
29.08.2025
Poland Poland
Recruiting
29.08.2025
Spain Spain
Recruiting
29.08.2025
The Netherlands The Netherlands
Recruiting
29.08.2025

Trial locations

Investigated drugs:

Povorcitinib is a medication being studied for long-term safety evaluation. It is an investigational drug that works by targeting specific proteins involved in inflammation. The medication is taken orally and is being tested to understand how well it performs and how safe it is when used over an extended period. This is a continuation study for patients who have previously participated in clinical trials using this medication.

Hidradenitis Suppurativa – A chronic skin condition that causes small, painful lumps to form under the skin, typically in areas where skin rubs together. The condition commonly affects areas with sweat glands, such as armpits, groin, and under the breasts. The lumps can break open, leading to tunnels under the skin and scarring.

Prurigo Nodularis – A skin condition characterized by hard, itchy lumps (nodules) that develop on the skin. These nodules typically appear on the arms, legs, and trunk of the body. The intense itching often leads to a cycle of scratching and further nodule formation.

Vitiligo – A condition where patches of skin lose their color due to the destruction of pigment-producing cells called melanocytes. The depigmented patches can appear anywhere on the body, often starting on the hands, face, or areas around body openings. The patches may gradually become larger over time.

Trial ID:
2024-520107-12-00
Protocol code:
INCB054707-801
NCT ID:
NCT06855498
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • ICP-332 for Adults with Prurigo Nodularis

    Recruiting

    2 1
    Austria Belgium France Germany Poland
  • Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

    Recruiting

    2 1
    Germany The Netherlands Poland Spain